- Home
- CELH vs MDGL Comparison
CELH vs MDGL Comparison
Compare CELH & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELH | MDGL |
|---|---|---|
| Founded | 2004 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Beverages (Production/Distribution) | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 10.0B |
| IPO Year | 2008 | 2005 |
Fundamental Metrics
Financial Performance| Metric | CELH | MDGL |
|---|---|---|
| Price | $41.44 | $442.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 12 |
| Target Price | $66.50 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 5.4M | 321.8K |
| Earning Date | 05-28-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 41.32 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $1,318,014,000.00 | $180,133,000.00 |
| Revenue This Year | $35.89 | $58.70 |
| Revenue Next Year | $11.06 | $46.88 |
| P/E Ratio | $175.82 | ★ N/A |
| Revenue Growth | ★ 101.65 | N/A |
| 52 Week Low | $30.78 | $265.00 |
| 52 Week High | $66.74 | $615.00 |
Technical Indicators
Market Signals| Indicator | CELH | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 36.41 | 44.63 |
| Support Level | $37.45 | $416.43 |
| Resistance Level | $47.24 | $446.51 |
| Average True Range (ATR) | 2.21 | 15.54 |
| MACD | -0.36 | 3.66 |
| Stochastic Oscillator | 0.95 | 67.00 |
Price Performance
Historical ComparisonAbout CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. The firm now owns three energy drink brands: Celsius, Alani Nu, and Rockstar Energy. It dedicates its efforts to product innovation and marketing while outsourcing manufacturing and packaging to third-party co-packers and distribution to PepsiCo. The firm issued convertible preferred shares following PepsiCo's investments in 2022 and 2025, giving the latter an 11% stake in Celsius.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.